EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations

Lavinia Alice Bălăceanu, Cristiana Grigore iD, Ion Dina, Cristian-Dorin Gurău, Mara Mădălina Mihai iD, Beatrice Bălăceanu-Gurău iD

Journal of Clinical Medicine · 11.06.2025 · 14 (12) · 4152

DOI: 10.3390/jcm14124152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.06.2025. Verfasst von Lavinia Alice Bălăceanu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Semiology, "Sf. Ioan" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romani…. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Carbohydrate antigen 125 (CA125) is a glycoprotein commonly overexpressed in epithelial ovarian cancer and widely recognized as a tumor marker. However, elevated CA125 levels are also observed in various non-malignant conditions, including diseases affecting mucosal surfaces, pleural or peritoneal effusions, cirrhosis (with or without ascites), endometriosis, uterine fibroids, adenomyosis, pelvic inflammatory disease, and pregnancy. This review aims to explore the role of CA125 in non-malignant serous effusions, highlighting its diagnostic and prognostic potential beyond the realm of oncology.

Methods

A comprehensive literature search was conducted across multiple databases and clinical trial registries. Eligible studies included full-text original research articles, reviews, and case reports published in English over the past 10 years. Inclusion criteria were limited to studies involving human subjects and focused on the role of CA125 in non-malignant serous effusions.

Results

CA125 is produced by coelomic epithelial cells lining the ovary, pleura, pericardium, and peritoneum. Its serum concentration is not significantly influenced by age, body weight, or renal function, even in the advanced stages of the disease. In peritoneal conditions, CA125 is synthesized by mesothelial cells and serves as a potential marker of peritoneal involvement. The prevailing pathophysiological mechanism suggests that mechanical stretching of mesothelial cells due to ascitic pressure stimulates CA125 release. Similarly, in heart failure, mesothelial cells of the pericardium produce CA125, which correlates with congestion severity, supports risk stratification, and may inform diuretic therapy.

Conclusions

While a threshold of 35 U/mL is established for malignancy, no standardized cutoff exists for CA125 in non-malignant conditions. The utility of CA125 measurement in peritoneal, pleural, or pericardial effusions—and cardiovascular diseases such as acute heart failure—for purposes of differential diagnosis, treatment guidance, or prognostication warrants further investigation through prospective clinical trials.

Schlagwörter

Stichwörter der Autor:innen

CA125biomarkersheart failurenon-malignant ascitisserous effusions

Autor:innen und Institutionen

  • Department of Medical Semiology, "Sf. Ioan" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Internal Medicine Clinic, "Sf. Ioan" Clinical Emergency Hospital, 042122 Bucharest, Romania.
  • Clinical Department of Gastroenterology, "Sf. Ioan" Clinical Emergency Hospital, 042122 Bucharest, Romania.
  • Orthopedics and Traumatology Clinic, Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Oncologic Dermatology, "Elias" Emergency University Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Research Institute of the University of Bucharest, University of Bucharest, 050663 Bucharest, Romania.

ORCID-Profile: Cristiana Grigore, Mara Mădălina Mihai, Beatrice Bălăceanu-Gurău

Zitieren

APA

Bălăceanu, L. A., Grigore, C., Dina, I., Gurău, C. D., Mihai, M. M., & Bălăceanu-Gurău, B. (2025). CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations. Journal of Clinical Medicine, 14(12), 4152. https://doi.org/10.3390/jcm14124152

Vancouver

Bălăceanu LA, Grigore C, Dina I, Gurău CD, Mihai MM, Bălăceanu-Gurău B. CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations. Journal of Clinical Medicine. 2025;14(12):4152. doi:10.3390/jcm14124152

BibTeX
@article{Blceanu2025,
  author = {Bălăceanu, Lavinia Alice and Grigore, Cristiana and Dina, Ion and Gurău, Cristian-Dorin and Mihai, Mara Mădălina and Bălăceanu-Gurău, Beatrice},
  title = {CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {12},
  pages = {4152},
  doi = {10.3390/jcm14124152}
}
Kostenlos starten →